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Abstract
Prenatal and early life neurodevelopment is exquisitely sensitive to insult from environmental exposures. Identifying
the effects of environmental toxicants on neurodevelopmental disorders is particularly important from a public health
perspective because many of these exposures are modifiable and may be targeted for intervention. Studying these
associations in prospective cohort studies that measure quantitative, dimensional traits related to neurodevelopmental
disorders, using standardized instruments such as psychometric tests or rating scales, mitigates many of the challenges
that arise when studying clinically diagnosed disorders. We consider validity and feasibility impacts resulting from this
design approach, including: 1) enhanced prospective exposure assessment with high quality environmental measures
during developmentally relevant windows; 2) reduced bias because studies of continuous outcomes do not recruit
cases and controls and are therefore not vulnerable to control selection bias; 3) enhanced statistical power because
traits are measured on all individuals in the cohort and power is not limited by the number of cases; 4) reduced
outcome misclassification because measuring quantitative traits avoids lumping together individuals with very
heterogeneous phenotypes into one category. We use autism spectrum disorders (ASD) as an example to illustrate the
advantages of this approach. Investigating the determinants of neurodevelopmental disorders – particularly modifiable
determinants such as environmental toxicant exposures – is of great public health importance, given the apparent
substantial rise of disorders like ASD over the past few decades. The use of prospective designs measuring quantitative,
dimensional traits offers a powerful opportunity to provide important clues to the etiology of these disorders and is
likely to accelerate our understanding of the role of environmental toxicant exposures as risk factors.
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Background
The human brain is exquisitely sensitive to the impacts of
environmental toxicant exposures during development [1]
and can serve as the “canary in the coal mine” for such
exposures – acting as an early warning sign for harmful
health effects. Identifying the effects of environmental tox-
icants on neurodevelopment is particularly important
from a public health perspective because many of these
exposures are modifiable and may be targeted for inter-
vention. Yet, previous epidemiologic studies of develop-
mental toxicants address only a fraction of the thousands
of chemicals now in our environment [2]. There is an
urgent need to accelerate investigation of environmental
toxicants and neurodevelopment and to improve methods
to enhance study validity and feasibility.
We propose that prospective cohort studies (often
referred to as longitudinal studies when they have repeated
measures of an outcome) that measure quantitative, dimen-
sional traits related to neurodevelopmental disorders offer
an efficient and valid approach for investigating associations
with environmental toxicants. We consider several advan-
tages of this design, and use autism spectrum disorders
(ASD) – a complex disorder with core traits that include
impairment in social communication and interaction, and
restricted, repetitive patterns of behaviors and interests – as
an illustrative example.
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Prospective studies enhance exposure assessment
Studies of developmental disorders, such as ASD, tend to
use case–control designs to ensure a sufficient number of
cases of these relatively rare outcomes (ASD prevalence
in the U.S. is currently 1.5%) [3]. These designs typically
reconstruct historical exposures corresponding to the
pertinent developmental window – the prenatal and early
life periods – which are likely to be the most critical
windows for effects of toxicant exposures on neurodevelop-
ment [4,5]. Retrospective exposure measurement is typic-
ally limited to parent recall or linkage to historical data (e.g.
air pollutant monitors), and therefore incurs a moderate
degree of exposure measurement error; this error would be
expected to attenuate measured associations, possibly
masking true associations. In addition, for some toxicants
valid retrospective exposure assessment may not be avail-
able, precluding them from study with these designs. In
contrast, prospective studies, which recruit participants
before the development of the outcome, can dramatic-
ally improve the quality of exposure data by quantifying
environmental toxicant exposures during developmen-
tally relevant windows (time points during development
when an insult has greatest potential impact on subse-
quent development), and employing the most accurate,
objective, quantitative measures, such as biomarkers or
micro-environmental measurements.
Prospective cohort studies are not vulnerable to control
selection bias
Case–control studies also face threats to validity from
problems with control group selection. For example, a
selection bias may arise when factors distinguish the ASD
case group from the underlying population above and
beyond having symptoms of ASD, such as race, socioeco-
nomic position, or access to health services. Children
diagnosed with ASD have been shown to differ along these
dimensions compared to the underlying population [6]. If
the sampling of the control group does not account for
these factors influencing diagnosis, the control group will
fail to represent the exposure distribution in the population
that gave rise to the cases and study results may be biased.
In contrast, prospective cohort studies of quantitative, di-
mensional traits related to a disorder avoid the problem of
a potentially biased control group entirely. There is no de-
fined case or control group; rather, all children enrolled are
assessed for behavioral traits that fall along a continuum.
Analyzing continuously distributed traits enhances
statistical power
A neurodevelopmental disorder can be conceptualized
as an extreme impairment along a dimension of an
underlying behavioral trait. For example, individuals with
ASD have severe impairment in social cognition. Social
cognition can be measured in the general population
with neuropsychological tests or parent/teacher-rated
behavioral scales, and, like intelligence, exhibits a fairly
normal distribution, with ASD falling at the extreme end
[7,8]. A notable limitation of prospective cohort studies
is that they are typically underpowered to investigate
associations with clinically diagnosed neurodevelopmental
disorder due to the rarity of these disorders, leading to
insufficient sample size. For example, a prospective study
of 1000 participants, considered large by environmental
epidemiologic standards, would yield approximately 15
cases of ASD over the duration of the study, which does
not lend itself to a feasible analysis. To address limitations
in sample size, prospective studies commonly measure
dimensional traits related to a disorder. This enhances
statistical power because traits are measured on all in-
dividuals in the cohort and compared across a range of
impairment in relation to an environmental toxicant
exposure; power is therefore not limited by the number
of cases in the cohort.
Analyzing quantitative, dimensional traits reduces
outcome misclassification
For many aspects of health, the critical issue is not
whether an individual “has” the disorder, but “how much of
it” [9]. Studies of clinically diagnosed disorder, which are
often complex disorders with a range of signs, symptoms,
and levels of severity, typically lump together individuals
with very heterogeneous phenotypes into one category,
often due to statistical constraints (a study would require a
large number of participants to look at subtypes of a
disorder). Heterogeneity of the case definition for these
complex disorders is problematic for etiologic research
because different etiologic factors may be at play for the
various traits that are included in the diagnostic criteria.
This has been cited as a major limitation for research on
ASD [10] and the research community has responded with
an effort to create new dimensional classifications of mental
disorders based on pathophysiology through the Research
Domain Criteria (RDoC) initiative [11]. Heterogeneity in
current categorical diagnosis introduces noise that could
lead to underestimation of an exposure-outcome associ-
ation. Examination of a single trait shared by cases of a
disorder (e.g., impaired social cognition in ASD) reduces
outcome heterogeneity and may allow for identification of
a more specific exposure-related biologic pathway.
By measuring decrements in a behavioral trait instead of
a diagnosed disorder, studies are also immune to temporal
changes in diagnostic criteria. For example, the definition
of ASD in the Diagnostic and Statistical Manual (DSM) of
Mental Disorders has undergone substantial changes in
recent years, and these changes have resulted in different
ASD prevalence estimates across DSM adaptations [12].
An additional challenge resulting from the heteroge-
neous nature of these developmental disorders is that
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children with mild or early manifestations of a disorder
may not meet diagnostic criteria but share similar behav-
ioral challenges. This again leads to outcome misclassifica-
tion, where a subset of individuals does not get classified
as cases because they narrowly miss the current diagnostic
criteria, but exhibit traits that share etiology with cases.
This misclassification does not arise with continuously
distributed traits because there is no cutoff or case criteria.
Instead, these more mildly affected individuals are more
appropriately considered along their numeric range be-
tween “normal” and “affected”.
Limitations
We have focused primarily on the benefits of prospective
studies of quantitative, dimensional traits for the study
of environmental toxicant exposures. Limitations of this
approach exist, including that much of the data collected
on behavior comes from rating scales, completed by the
parent, teacher or self-completed. These data may be
considered more subjective than other neuropsychological
test data, however they can provide information about
function in multiple settings (e.g., home, school) and are
fairly inexpensive and easy to administer. Other quantita-
tive measures, such as brain imaging technologies, while
not directly measuring behavioral manifestations, may
offer promise in providing objective quantitative measure-
ment of aspects of a neurodevelopmental disorder.
Another limitation is that a given trait, such as impaired
social cognition, may be shared by other behavioral disor-
ders, such as attention deficit hyperactivity disorder
(ADHD). This overlap could pose challenges for infer-
ring associations with clinically diagnosed ASD, though
the high comorbidity of such disorders suggests that
they may not be completely etiologically distinct.
From a clinical perspective, exposure-related decrements
that do not move a child into a clinically diagnosed cat-
egory may be considered unimportant because function
remains “within normal limits”. However, small decrements
in function are important from a population perspective, as
small shifts in the mean for a population can translate into
an increase in the number of cases of clinically diagnosed
disorder in that population [13].
We cite a number of advantages of cohort studies over
case–control studies for investigating environmental toxi-
cant exposures and neurodevelopment, however a notable
limitation of the prospective cohort design is loss to follow-
up. In addition to the expense incurred in following up and
tracking participants in cohort studies, loss to follow up
can result in selection bias if attrition of participants is
related to both exposure and outcome.
Conclusions
Investigating the determinants of neurodevelopment dis-
orders – particularly modifiable determinants such as
environmental toxicant exposures – is of great public
health importance, given their apparent substantial rise
in prevalence over the past few decades. We conclude
that the use of prospective designs measuring quantita-
tive, dimensional traits underlying such disorders confers
substantial benefits to the feasibility and validity of epi-
demiologic studies of environmental toxicant exposures.
The risk of failing to pursue such studies is great, includ-
ing lack of developmental relevance in the measures of
exposure, limited statistical precision to resolve potential
relationships, low return on investment of data already
collected, and false negative findings or missed opportun-
ities when study designs have questionable validity. Studies
of quantitative, dimensional traits offers a powerful oppor-
tunity to provide important clues to the etiology of neuro-
developmental disorders and are likely to accelerate our
understanding of the role of environmental toxicant expo-
sures as risk factors for disorders such as ASD.
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